<SEC-DOCUMENT>0001638833-25-000122.txt : 20250922
<SEC-HEADER>0001638833-25-000122.hdr.sgml : 20250922
<ACCEPTANCE-DATETIME>20250708073049
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001638833-25-000122
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ifb072b23b96d454099f8be21fbe1dafa_78"></div><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="splogoa.jpg" src="splogoa.jpg" style="height:55px;margin-bottom:5pt;vertical-align:text-bottom;width:448px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 8, 2025 </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIA EDGAR</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States Securities and Exchange Commission</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Division of Corporation Finance</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office of Industrial Applications and Services</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Re&#58; Surgery Partners, Inc. </font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K for the Year Ended December 31, 2024</font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">File No. 001-37576</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ladies and Gentlemen,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On behalf of Surgery Partners, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;), set forth below are the Company&#8217;s responses to the comments of the staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;SEC&#8221;) within the letter dated June 26, 2025, relating to the Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 7, 2025 (the &#8220;2024 Form 10-K&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this letter, we have recited the comments from the Staff in italicized type and have followed each comment with the Company&#8217;s response in ordinary type. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K for Fiscal Year Ended December 31, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">1. Organization and Summary of Accounting Policies </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues, page F-10</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">We note your disclosures that the transaction price for patient service revenues is based on gross charges net of estimated contractual adjustments and implicit price concessions. We further note your disclosure that contractual allowances are recorded at the time of payment for surgical hospitals and the time of billing for ASCs. Explain what you mean by contractual adjustments versus contractual allowances and the specific reference to the authoritative literature that supports the timing for recognizing contractual allowances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and, in response to the Staff&#8217;s comment, confirms to the Staff that the terms &#8220;contractual adjustments&#8221; and &#8220;contractual allowances&#8221; are used interchangeably by the Company and have the same meaning.  We determine the transaction price in accordance with ASC 606, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Our disclosure was referring to the timing of when contractual adjustments are recorded in our patient accounting systems. However, all revenue transactions are recognized net of estimated contractual adjustments at the time that performance obligations are satisfied, which is generally at the time of service. The Company will revise any discussion of the transaction price in future filings consistent with the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments and implicit price concessions. The Company estimates its contractual adjustments and implicit price concessions based on contractual agreements, its discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments are recognized at the time of services being performed, with ASCs typically based on contractual agreements and surgical hospitals typically based on historical experience of cash collections and write-offs.  Changes in estimated contractual adjustments are recorded in the period of change, with final adjustments, if any, typically at the time of payment.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9. Income Taxes, page F-26</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">We note that the valuation allowance against deferred tax assets increased during fiscal year 2024 by $134.6 million, of which $115.4 million is disclosed in the effective tax rate reconciliation as a change in federal valuation allowance, which significantly exceeds the amounts recognized during the two previous fiscal years. Please provide a comprehensive explanation here or within MD&#38;A that provides investors with an understanding of the specific facts and circumstances that led to the significant increase in the valuation allowance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and, in response to the Staff&#8217;s comment, the Company notes that the increase in the valuation allowance during fiscal year 2024 is attributable to the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we were in a cumulative three-year pre-tax loss position for financial reporting purposes while as of December 31, 2023, we were in a cumulative three-year pre-tax income position for financial reporting purposes. The change in 2024 to a three-year cumulative loss position was considered objectively verifiable significant negative evidence, for which we did not have sufficient positive evidence to overcome.  Therefore, in accordance with ASC 740-10-30, we recorded a full valuation allowance, net of future reversing deferred tax liabilities, on our deferred tax assets to reflect the net realizable value of our deferred tax assets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent applicable in future filings, we will provide a more comprehensive explanation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">14. Segment Reporting, page F-31</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Please tell us whether you believe equity in earnings of unconsolidated affiliates and net income attributable to non-controlling interests represent significant segment expenses determined in accordance with ASC 280-10-50-26A. If so, please provide us with an explanation as to why each line item is a significant segment expense. Alternatively, if these amounts are other segment items as addressed in ASC 280-10-50-26B, it appears that these amounts should be aggregated with the other segment expense, net line item into one other segment items line item. Please correspondingly provide a qualitative description of the composition of other segment items in accordance with ASC 280-10-50-26B.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and, in response to the Staff&#8217;s comment, we advise the Staff that we do not believe equity in earnings of unconsolidated affiliates and net income attributable to non-controlling interests represent significant segment expenses. The Company further submits that it will revise its disclosure in future filings to aggregate these amounts with the other segment expense, net line item into one other segment items line item. Additionally, the Company will expand its disclosure in future filings to correspondingly provide a qualitative description of the composition of other segment items.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">With regards to the Corporate and other unallocated expenses in your reconciliation of Adjusted Surgical Facilities EBITDA to consolidated income before income taxes, please revise this presentation to separately disclose revenue and expenses from other business activities that are not considered reportable segments in an &#8220;all other&#8221; category in accordance with ASC 280-10-50-15 and separately identify and describe all significant reconciling items in accordance with ASC 280-10-50-31.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company respectfully acknowledges the Staff&#8217;s comment and, in response to the Staff&#8217;s comment, we advise the Staff that no revenues are within the Corporate and other unallocated expenses, which represents corporate overhead expenses that are not allocated to the Surgical Facilities reportable segment. The Company will revise its presentation of Corporate and other unallocated expenses in future filings to separately identify and describe all significant reconciling items within the Unallocated amounts line item consistent with the illustrative example provided for in ASC 280-10-55-48.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please direct any questions or further comments you may have regarding the 2024 Form 10-K or this response letter to the undersigned at 615-234-5900.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SURGERY PARTNERS, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David T. Doherty</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David T. Doherty</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cc&#58; &#160;&#160;&#160;&#160;Eric Evans, Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jennifer Baldock, Executive Vice President, Chief Administrative &#38; Development Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Neil Zieselman, Senior Vice President, Corporate Finance &#38; Controller</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>splogoa.jpg
<DESCRIPTION>SP LOGO
<TEXT>
begin 644 splogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !, F0# 2(  A$! Q$!_\0
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M^!]64445Y1[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]B&WCC^#\TBHHD?5)M[ <MA4QDT >]:1I-IH>FVMA8P):VEM&(HH8QA44#
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M\#AT<>H(X-6Z^3OV)[Z^TS7_ !MX6:\^V:9I\H:$Y)4.'="R^@8*#CVKZQH
M**** "D8;ABEHH Q[CPCI%U,\TMC#)(YW,Q'))[U'_PA6B?] Z#\JW**=V3R
MKL>:_$CPWIVEZ3!<6ELEO)YNP^7P""#U_*N)\._\AW3_ /KNG\Z])^+'_(OP
M?]=U_D:\V\/_ /(<L/\ KNG\Q753^ Y*GQGB?[2/_)8M=_[8_P#HI*Z']ESP
M)HGC37-:.M6,>H):PQF*.4G:"S$$X[GBN>_:2_Y+%KO_ &Q_]%)7H'[&?_(:
M\2_]<(?_ $)J]>I)QPMUV1\Q2BI9A:2NKO\ 4]P_X47X$_Z%BP_[X/\ C1_P
MHOP'_P!"Q8#_ ( ?\:[RBO!]I/\ F9];["E_*ON&0Q+!&L:#:B@*JCL!3F&Y
M2*6BLS<^3M8^!_Q8^%OB'4-3^'>O_P!H:==3O<-I\CJI!9LD&-_D/IN!!IR?
M%S]H>R*V\O@"VN)>AD-E(0?Q67;7U?10!\D7/PK^,'Q[O;2+Q]<P^&_#D4HD
M:S@V[F^B*3D^[MQGI7U/X?T.S\,Z+8Z3I\0ALK.%8(8QV51@?C6A10!XS^T!
M^SU;_%Z&UU*PNQI?B6Q7;!=$';(N<A'QR,'D,.1D]:\NL_$7[1WP[A%C/HD/
MBB"(;4N)$%P2.WS(ZL?^!#-?6]% 'R5=:Y^T;\28OL$>D0^$[:4;9+E5%N0.
M_P SLSC_ (",UZQ\!?V?['X.65Q=SW7]J^(KY<75ZRX"C.=B9YQGDD\D@?2O
M7:* $/0UX#^RW\+_ !)\.;SQB^OV LEU"YBDMR)4?>H,F3\I./O#K7O]% !7
M@?[27P,U'QI/IOBOP@!%XNTV1,;'$9F0'*G<3C<AY&>Q(]*]\HH YWP#?:YJ
M7A6QE\1Z=_9>M>6$NK=75UWC@LI4D8/7';.*\[^.7[-FC_%S&IP3_P!D>(X5
M"I?1IN64#HLB]\=F'(]^E>S44 ?(MBG[1GPL1;.&WB\6Z?",1O(5N>![Y63\
MZNK\4OVBM<0P6W@:UT^0G'G-:-'C_OY+C]*^K:* /F'X:?L^^.K[XH6'Q \?
M:U;G4;9PZVL"AW;"E0K%0%4#/;->^?$;2[G7/A_XDTVRC\Z\O-.N+>&/(&YV
MC95&3P.2*Z*B@#XL^'_@K]H7X9:"=(T#3;:VL3,TY21K60[V !.6.?X173?;
MOVH/^?2S_P"^;3_&OJVB@#PKX.77QJF\8;?'T%O'H7V=\&);<'S<C;]PY]:T
M_P!J3P!KGQ(^&L>D^'[07M\+^*8QF14^0*X)RQ [BO8J* .>^'NEW.B>!_#^
MG7L?E7=II\$$R9!VNL8##(Z\BMVXA2XADBE19(W4JRL,@@C!!%244 ?,OA/X
M1>+_ (*_&BZO/"EA_:7@75"/M-N+A$:!23T#,,F,Y(/=3CK7TROW12T4 <]\
M0M+N=<\"^(M.LX_-N[O3KB"&/(&YVC95&3P.2*\^_9;\ ZY\.?AJVDZ_:"RO
MC?2S>6)%?Y65<'*DCL:]BHH **** $;[IKY\\$_"SQ-I/[4/B/Q?=:>(] O(
MI4AN?-0EB1&!\H.X?=/:OH2B@ HHHH ^?_VH/ /C/XJ77A_P]H=E_P 2!9EG
MO[QID4!BVT?*3N(1=S<#G</2O;O#FAVGAG0=/TJPC$5G9P)!$OHJC K2HH *
M\Y^/GPS_ .%J?#?4M)B56U&,"YL2V!^^3) R>FX$K_P*O1J* /*_V<=*\5^&
M_AU:Z'XML#9WFFNT-N_G))YD'5>5)QMR5^@%<A8?"[Q+!^UI?>,WT\#P[)!L
M2Z\U,D_9E3[N=WW@1TKZ#HH 2O.?CM\([7XO>![G36VQ:E!^^L+@C_5RCL3_
M '6Z'\^PKT>B@#R;]G:V\;:+X/70_&NFM;W.G 16MWYZ2^=#V4[6)RN,9/48
M]*]8I:* /GZ]^%_B6;]K.Q\:)8 ^'8K?RWNO-3(;[,R?=SN^\0.E?0-%% "5
M\_?L]_"WQ+X%^)/CS5=9L!:V.J3L]K()4?>#,[= 21P1UKZ"HH *Y7XE?#W2
M_B;X3N]"U6/,4PW1S*/GAD ^61?<?J,CO7544 ?,_P"RS\$O%'PE\8^)9-;M
M8ULIH%@MKJ.566;;)G(4'(R.>17HW[27@S6/'_PIU'1=#M?MFHS30.D1=4R%
MD!/+$#H*]2HH ^/_  UI?[27A+0;'1M-L+2*PLHA#"C?9&(4=!DG)K3^W?M0
M?\^EG_WS:?XU]6T4 >4_ ^;XFS+JW_"QXH8W#1?8O)$(R/FWY\L_[O6N1_:=
M^%?B7XB>)O!-UH.GB\@TV9WN6,J)L!>,C[Q&>%/3TKZ$HH 1?NBLKQ1X9L/&
M&@WVCZG"MQ8WD1BEC;N#W'H0<$'L0*UJ* /G;]GSX?\ COX/^+-6\.7MI_:/
M@J:9Y+34%G3,3=FV;MP##@C'! /K6G\>_@CXD\;^)-/\5^#]?;2->L+?[,L1
M=HPZ[F;AUZ')Z$8->[44 ?)D7CK]H_PBGV>\\,0:]M^43FW64GWS"ZY_$4MU
MKG[1?Q(M6TY=%M?"MK.-DETJ>0P4]>7=G'_ 1FOK*B@#S#X#_!.S^#/AN6V6
MX^W:K>.);V\VX#L!PJC^Z,GKUR3WQ7I]%% !1110 4444 %%%% ',>/M#N]?
MTF.WLU5I%E#D,P'&#_C7)>'?AOJEOJ]M/=B.&&%PY*N&)QVXKU.C&*T4W%61
MFZ:D^9GS1\=OV>_$'B_QG+KN@B&Z2[11-#+*(VC95"Y&>"" *W/V;_A-XC^&
M^IZU-KEM%!'=11K$8YE?)5B3T/O7O=&*W>*J.G[)['%' THUO;J]Q:***Y#T
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
